Ensysce Biosciences (ENSC) Cash from Operations (QoQ) (2018 - 2025)
Ensysce Biosciences (ENSC) Cash from Operations (QoQ) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 31.06% |
| Jun 30, 2025 | -58.54% |
| Mar 31, 2025 | -123.46% |
| Dec 31, 2024 | 25.11% |
| Sep 30, 2024 | 55.83% |
| Jun 30, 2024 | 32.23% |
| Mar 31, 2024 | -89.16% |
| Dec 31, 2023 | 20.36% |
| Sep 30, 2023 | 27.21% |
| Jun 30, 2023 | 13.82% |
| Mar 31, 2023 | -9.45% |
| Dec 31, 2022 | 50.92% |
| Sep 30, 2022 | -51.21% |
| Jun 30, 2022 | -29.20% |
| Mar 31, 2022 | 8.78% |
| Dec 31, 2021 | 1.49% |
| Sep 30, 2021 | -2,790.82% |
| Jun 30, 2021 | 74.42% |
| Mar 31, 2021 | 3.13% |
| Dec 31, 2020 | -249.13% |